{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Purpura%2C+Thrombocytopenic&page=6",
    "query": {
      "condition": "Purpura, Thrombocytopenic",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 140,
    "total_pages": 14,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Purpura%2C+Thrombocytopenic&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Purpura%2C+Thrombocytopenic&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T21:17:20.284Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04188379",
      "title": "A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immune Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "efgartigimod",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 131,
      "start_date": "2019-12-16",
      "completion_date": "2022-02-03",
      "has_results": true,
      "last_update_posted_date": "2025-03-13",
      "last_synced_at": "2026-10-14T21:17:20.284Z",
      "location_count": 9,
      "location_summary": "Tucson, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04188379"
    },
    {
      "nct_id": "NCT00706342",
      "title": "Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Purpura, Thrombocytopenic, Idiopathic"
      ],
      "interventions": [
        {
          "name": "Fostamatinib Disodium / R935788",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rigel Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 18,
      "start_date": "2007-01",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2016-06-03",
      "last_synced_at": "2026-10-14T21:17:20.284Z",
      "location_count": 2,
      "location_summary": "New York, New York • Cleveland, Ohio",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00706342"
    },
    {
      "nct_id": "NCT00244257",
      "title": "Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Idiopathic Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "GMA161",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2005-08",
      "completion_date": "2008-07",
      "has_results": false,
      "last_update_posted_date": "2015-04-09",
      "last_synced_at": "2026-10-14T21:17:20.284Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • San Diego, California • Bethesda, Maryland + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00244257"
    },
    {
      "nct_id": "NCT00625443",
      "title": "Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "Blinded (placebo)",
          "type": "DRUG"
        },
        {
          "name": "Open Label (Avatrombopag tablets)",
          "type": "DRUG"
        },
        {
          "name": "Blinded (Avatrombopoag tablets)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2007-05",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2018-03-16",
      "last_synced_at": "2026-10-14T21:17:20.284Z",
      "location_count": 12,
      "location_summary": "Anaheim, California • Bakersfield, California • Manchester, Connecticut + 8 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Manchester",
          "state": "Connecticut"
        },
        {
          "city": "New Port Richey",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00625443"
    },
    {
      "nct_id": "NCT01437384",
      "title": "Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Idiopathic Thrombocytopenic Purpura (ITP)"
      ],
      "interventions": [
        {
          "name": "E5501",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 36,
      "start_date": "2011-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-05-21",
      "last_synced_at": "2026-10-14T21:17:20.284Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01437384"
    },
    {
      "nct_id": "NCT04516967",
      "title": "Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Immune Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "Avatrombopag",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sobi, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Year to 17 Years"
      },
      "enrollment_count": 75,
      "start_date": "2021-03-05",
      "completion_date": "2025-10-28",
      "has_results": true,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-10-14T21:17:20.284Z",
      "location_count": 21,
      "location_summary": "Phoenix, Arizona • Long Beach, California • Orange, California + 18 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04516967"
    },
    {
      "nct_id": "NCT07104565",
      "title": "Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immune Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "INCA000585",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2025-12-29",
      "completion_date": "2028-03-09",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-14T21:17:20.284Z",
      "location_count": 9,
      "location_summary": "Glendale, Arizona • Los Angeles, California • Lone Tree, Colorado + 6 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Lone Tree",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Cooper City",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07104565"
    },
    {
      "nct_id": "NCT05885555",
      "title": "A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Immune Thrombocytopenia (ITP)"
      ],
      "interventions": [
        {
          "name": "Ianalumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 41,
      "start_date": "2023-08-16",
      "completion_date": "2029-03-19",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-14T21:17:20.284Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05885555"
    },
    {
      "nct_id": "NCT01151423",
      "title": "Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acquired Thrombotic Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "Caplacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Ablynx, a Sanofi company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2011-01",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2023-04-04",
      "last_synced_at": "2026-10-14T21:17:20.284Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01151423"
    },
    {
      "nct_id": "NCT03810352",
      "title": "Association of Platelet Parameters With Bleeding Severity in Children With ITP",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Immune Thrombocytopenia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "6 Months to 20 Years"
      },
      "enrollment_count": 95,
      "start_date": "2019-03-15",
      "completion_date": "2023-11-26",
      "has_results": false,
      "last_update_posted_date": "2024-03-15",
      "last_synced_at": "2026-10-14T21:17:20.284Z",
      "location_count": 6,
      "location_summary": "Aurora, Colorado • Boston, Massachusetts • New York, New York + 3 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03810352"
    }
  ]
}